Steven, Daniel and Troy cover the last two
week sof various Nintendo goings - on, along with some discussion around Switch games being more expensive than the same game on other p...
Not exact matches
Just over a
week before the deadline with
SOF, American Apparel found a white knight: Lion Capital, a private - equity group in London, that invested US$ 80 million.
Results presented today at The International Liver Congress ™ 2015 demonstrate that hepatitis C (HCV)- infected genotype - 3 (GT - 3) patients, with and without cirrhosis, receiving 24
weeks of sofosbuvir (
SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12
weeks (SVR12), observed in a Phase 3 study, to date.
The 12 -
week combination of
SOF / DCV / RBV achieved a 100 % SVR4 rate in cirrhotic patients without the additive effect of extension of the treatment to 24
weeks with or without RBV (95.7 % and 92.5 %, respectively), and this was also true in experienced patients.
All non-cirrhotic patients achieved 100 % SVR4 at 12
weeks, demonstrating that the 12 -
week combination of
SOF / DCV is a proven therapeutic option.
Overall, the sustained virologic response rate at 4
weeks (SVR4) for
SOF / DCV was 81.6 % after 12
weeks of treatment and 93.9 % following 24
weeks of treatment.
A study presented today that evaluated an investigational dosage of once - daily ledipasvir 45 mg / sofosbuvir 200 mg (LDV /
SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99 % of children (n = 89/90) had undetectable levels of HCV - RNA 12
weeks after treatment.
As part of a compassionate use program, 104 post-liver transplant patients with recurring HCV who had exhausted all treatment options and had poor clinical prognoses, received sofosbuvir (
SOF) and ribavirin (RBV) with pegylated interferon (PEG) included at the physicians» discretion for up to 48
weeks.
The results show that 12
weeks of DCV -
SOF is a highly effective and well - tolerated treatment regimen for HCV in patients with HIV co-infection, including cirrhotic patients.